KRAS and neoplasm: We confirm the previous reports that PRNRP is pathologically characterized by papillary or tubulopapillary architecture with frequently cystic change, low-grade tumor cells with oncocytic cytoplasm and inverted nuclear location, diffuse and strong expression of GATA3 and 34βE12, and recurrent KRAS mutation.